Objective: To determine if hydroxychloroquine (HCQ) reduces the incidence of new illness, hospitalization or death among outpatients at risk for or infected with SARS-CoV-2 (COVID-19).

Authors:.= Khan MS, Khan MS, Debnath Cr, Nath PN, Mahtab MA. PMID: 33293006 PMCID: PMC7837160 DOI: 10.1016/j.arbres.2020.08.007 Abstract The pandemic coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been spread rapidly worldwide with considerable morbidity and mortality. COVID-19 patients have various clinical presentations: asymptomatic, exhibit mild flu-like symptoms, be [...]

Authors: Luks AM, Swenson ER PMID: 32521167 PMCID: PMC7462317 DOI: 10.1513/AnnalsATS.202005-418FR Abstract During the ongoing coronavirus disease (COVID-19) pandemic, reports in social media and the lay press indicate that a subset of patients are presenting with severe hypoxemia in the absence of dyspnea, a problem unofficially referred to as "silent hypoxemia." To decrease the risk [...]

Authors:Burton MJ, Clarkson JE, Goulao B, Glenny AM, McBain AJ, Schilder AG. PMID:PMC8188293 DOI: 10.1002/14651858.CD013628.pub2 Abstract Background: COVID-19 infection poses a serious risk to patients and - due to its contagious nature - to those healthcare workers (HCWs) treating them. The risks of transmission of infection are greater when a patient is undergoing an aerosol-generating [...]

Authors: Zimering MB, Razzaki T, Tsang T, Shin JJ PMID: 33117497 PMCID: PMC7590925 Abstract Advanced age and medical co-morbidity are strong predictors of mortality in COVID-19 infection. Yet few studies (to date) have specifically addressed risk factors associated with COVID-19 mortality in a high-risk subgroup of older US adults having one or more chronic diseases. [...]

Authors:Meister TL, Briggemann Y, Todt D, Muller JA, Grob R. PMID: PMC7454736 DOI: 10.1093/infdis/jiaa471 Abstract The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic creates a significant threat to global health. Recent studies suggested the significance of throat and salivary glands as major sites of virus replication and transmission during early coronavirus disease 2019, [...]

Authors: Somi VK, Mehta A, Ratre YK, Tiwari AK, Amit A. PMID: PMC7832734 DOI: 10.1016/j.ejphar.2020.173551 Abstract The severity of the recent pandemic and the absence of any specific medication impelled the identification of existing drugs with potential in the treatment of Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Curcumin, known for its [...]

Authors: Hottz ED, Azevedo-Quintanilha Ig, Palhinha L, Teixeira L, Barreto EA PMID: 32678428 PMCID: PMC7483437 DOI: 10.1182/blood.2020007252 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent pathogen responsible for the coronavirus disease 2019 (COVID-19). Since its emergence, the novel coronavirus has rapidly achieved pandemic proportions causing remarkably increased morbidity and mortality around the [...]

Authors: Swargiary A DOI: https://doi.org/10.21203/rs.3.rs-73308/v1 Abstract Purpose: COVID-19, caused by SARS-CoV2 virus is a contagious disease affecting millions of lives throughout the globe. Currently, there are no clinically approved drugs for SARS-CoV2 although some drugs are undergoing clinical trials. The present study investigates the binding property of ivermectin on four important drug targets, spike protein, [...]

Authors: Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM PMID: 32702719 PMCID: PMC7336703 doi: 10.21203/rs.3.rs-30934/v3 Abstract SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine [...]